Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …

Ischemic lesions stimulate adult neurogenesis in the dentate gyrus, however, this is not
associated with better cognitive function. Furthermore, increased neurogenesis is …

Intravenous thrombolysis (IVT) represents the only systemic reperfusion therapy able to
reverse neurological deficit in patients with acute ischemic stroke (AIS). Despite its …

Stroke, the second highest leading cause of death, is caused by an abrupt interruption of
blood to the brain. Supply of blood needs to be promptly restored to salvage brain tissues …

Background and Objectives The role of IV thrombolysis (IVT) in patients with large vessel
occlusions (LVOs) administered before transfer from a primary stroke center (PSC) to a …

IVT is a highly effective systemic reperfusion therapy that counts 25 years of everyday
clinical experience but still presents several challenges in its application. Appropriate patient …

Acute stroke is the third leading cause of mortality and disability worldwide. Administration of
appropriate therapy for acute stroke is critically dependent on timely classification into either …

IVT and mechanical thrombectomy are two effective reperfusion therapies that should be
used in a swift and noncompeting fashion in AIS patients. AIS patients with LVO and no …

Objective: To evaluate the neuroprotective effect of resveratrol (RES) in rat models of
cerebral ischemia/reperfusion (I/R) injury. Data sources: PubMed, Embase, MEDLINE …